Tyler D. Hitchman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tyler D. Hitchman has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Emilie Ceraudo
Laboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, New York
10 shared publications - Ping Chi
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
10 shared publications - Thomas P. Sakmar
Laboratory of Chemical Biology and Signal Transduction, The Rockefeller University
10 shared publications - Yu Chen
Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
10 shared publications - Amanda R. Moore
Department of Research Oncology, Genentech, South San Francisco, USA
9 shared publications - Alexander Noor Shoushtari
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
8 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Supplementary figures S1-S6 with figure legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Supplementary figures S1-S6 with figure legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Purpose:All uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the G-protein alpha-q (Gαq) pathway. Targeting these melanomas has proven difficult despite advances in the molecular understanding of key driver signaling pathways in the disease pathogenesis. Inhibitors of Gαq have shown promising preclinical results, but their therapeutic activity in distinct Gαq mutational contexts and in vivo have remained elusive.Experimental Design:We used an isogenic melanocytic cellular system to systematically examine hotspot mutations in GNAQ (e.g., G48V, R183Q, Q209L) and CYSLTR2 (L129Q) found in human uveal melanoma. This cellular system and human uveal melanoma cell lines were used in vitro and in in vivo xenograft studies to assess the efficacy of Gαq inhibition as a single agent and in combination with MEK inhibition.Results:We demonstrate that the Gαq inhibitor YM-254890 inhibited downstream signaling and in vitro growth in all mutants. In vivo, YM-254890 slowed tumor growth but did not cause regression in human uveal melanoma xenografts. Through comprehensive transcriptome analysis, we observed that YM-254890 caused inhibition of the MAPK signaling with evidence of rebound by 24 hours and combination treatment of YM-254890 and a MEK inhibitor led to sustained MAPK inhibition. We further demonstrated that the combination caused synergistic growth inhibition in vitro and tumor shrinkage in vivo.Conclusions:These data suggest that the combination of Gαq and MEK inhibition provides a promising therapeutic strategy and improved therapeutic window of broadly targeting Gαq in uveal melanoma.See related commentary by Neelature Sriramareddy and Smalley, p. 1217
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Purpose:All uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the G-protein alpha-q (Gαq) pathway. Targeting these melanomas has proven difficult despite advances in the molecular understanding of key driver signaling pathways in the disease pathogenesis. Inhibitors of Gαq have shown promising preclinical results, but their therapeutic activity in distinct Gαq mutational contexts and in vivo have remained elusive.Experimental Design:We used an isogenic melanocytic cellular system to systematically examine hotspot mutations in GNAQ (e.g., G48V, R183Q, Q209L) and CYSLTR2 (L129Q) found in human uveal melanoma. This cellular system and human uveal melanoma cell lines were used in vitro and in in vivo xenograft studies to assess the efficacy of Gαq inhibition as a single agent and in combination with MEK inhibition.Results:We demonstrate that the Gαq inhibitor YM-254890 inhibited downstream signaling and in vitro growth in all mutants. In vivo, YM-254890 slowed tumor growth but did not cause regression in human uveal melanoma xenografts. Through comprehensive transcriptome analysis, we observed that YM-254890 caused inhibition of the MAPK signaling with evidence of rebound by 24 hours and combination treatment of YM-254890 and a MEK inhibitor led to sustained MAPK inhibition. We further demonstrated that the combination caused synergistic growth inhibition in vitro and tumor shrinkage in vivo.Conclusions:These data suggest that the combination of Gαq and MEK inhibition provides a promising therapeutic strategy and improved therapeutic window of broadly targeting Gαq in uveal melanoma.See related commentary by Neelature Sriramareddy and Smalley, p. 1217
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
List of Primers, antibodies, genesets, rna-seq geneset overlaps used in our study.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
List of Primers, antibodies, genesets, rna-seq geneset overlaps used in our study.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100163
Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100163
Open AccessDirect evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling
- Open Access
Uveal Melanoma Oncogene CYSLTR2 Encodes a Constitutively Active GPCR Highly Biased Toward Gq Signaling
The G protein-coupled receptor (GPCR) cysteinyl-leukotriene receptor 2 (CysLTR2) with a single amino acid mutation at position 3.43 (Leu replaced with Gln at position 129 in transmembrane helix 3) causes uveal melanoma in humans. The ability of CysLTR2-L129Q to cause malignant transformation has been hypothesized to result from constitutive activity. We show that CysLTR2-L129Q is a constitutively active mutant (CAM) that strongly drives Gq/11 signaling pathways in melan-a melanocytes and in HEK293T cells in culture. However, the mutant receptor only very weakly recruits beta-arrestins 1 and 2. The mutant receptor displays profound signaling bias while avoiding arrestin-mediated downregulation. The mechanism of the signaling bias results from the creation of a hydrogen-bond network that stabilizes the active G protein signaling state through novel interactions with the highly-conserved NPxxY motif on helix 7. Furthermore, the mutation destabilizes a putative allosteric sodium-binding site that usually stabilizes the inactive state of GPCRs. Thus, the mutation has a dual role of promoting the active state while destabilizing inactivating allosteric networks. The high degree of constitutive activity renders existing orthosteric antagonist ligands of CysLTR2 ineffective as inverse agonists of the mutant. CysLTR2 is the first example of a GPCR oncogene that encodes a GPCR with constitutive highly biased signaling that can escape cellular downregulation mechanisms.
Open AccessUveal Melanoma Oncogene CYSLTR2 Encodes a Constitutively Active GPCR Highly Biased Toward Gq Signaling
The G protein-coupled receptor (GPCR) cysteinyl-leukotriene receptor 2 (CysLTR2) with a single amino acid mutation at position 3.43 (Leu replaced with Gln at position 129 in transmembrane helix 3) causes uveal melanoma in humans. The ability of CysLTR2-L129Q to cause malignant transformation has been hypothesized to result from constitutive activity. We show that CysLTR2-L129Q is a constitutively active mutant (CAM) that strongly drives Gq/11 signaling pathways in melan-a melanocytes and in HEK293T cells in culture. However, the mutant receptor only very weakly recruits beta-arrestins 1 and 2. The mutant receptor displays profound signaling bias while avoiding arrestin-mediated downregulation. The mechanism of the signaling bias results from the creation of a hydrogen-bond network that stabilizes the active G protein signaling state through novel interactions with the highly-conserved NPxxY motif on helix 7. Furthermore, the mutation destabilizes a putative allosteric sodium-binding site that usually stabilizes the inactive state of GPCRs. Thus, the mutation has a dual role of promoting the active state while destabilizing inactivating allosteric networks. The high degree of constitutive activity renders existing orthosteric antagonist ligands of CysLTR2 ineffective as inverse agonists of the mutant. CysLTR2 is the first example of a GPCR oncogene that encodes a GPCR with constitutive highly biased signaling that can escape cellular downregulation mechanisms.